Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07158905 · ClinicalTrials.gov registry record · Phase 1
AV-1980R (Tau Vaccine) in Preclinical Alzheimer's Disease (TAURUS-1980)
A Phase 1 study, sponsored by Institute for Molecular Medicine.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT07158905 is a Phase 1 study that is actively recruiting participants, run by Institute for Molecular Medicine. The registered enrollment target is 48 participants.
The verdict
NCT07158905, a Phase 1 study, is actively recruiting participants, sponsored by Institute for Molecular Medicine.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
This is a Phase 1, multicenter, randomized, double-blind, placebo-controlled, multiple dose-escalating trial to evaluate the safety, tolerability, and immune response of AV-1980R, an investigational vaccine targeting tau protein, in participants with preclinical Alzheimer's disease. Up to 48 cognitively unimpaired adults aged 65-80 with biomarker evidence of early Alzheimer's disease will be enrolled into three ascending dose cohorts. The study is designed as a secondary prevention trial to test whether therapeutic immunization at the preclinical stage is safe, induces an immune response, and, exploratorily, may favorably affect biomarkers associated with disease progression.
Interventions
- OTHER Placebo
- BIOLOGICAL AV-1980R 20 µg
- BIOLOGICAL AV-1980R 60 µg
- BIOLOGICAL AV-1980R 180 µg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2026-06-23 |
| Est. Completion | 2029-10-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07158905
The ClinicalTrials.gov registry entry for NCT07158905 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Institute for Molecular Medicine, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT07158905 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07158905 about?
NCT07158905 is a clinical study titled "AV-1980R (Tau Vaccine) in Preclinical Alzheimer's Disease (TAURUS-1980)". This is a Phase 1, multicenter, randomized, double-blind, placebo-controlled, multiple dose-escalating trial to evaluate the safety, tolerability, and immune response of AV-1980R, an investigational vaccine targeting tau protein, in participants with preclinical Alzheimer's disease. Up to 48 cogniti...
What is the current status of trial NCT07158905?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2026-06-23. Estimated completion is 2029-10-15.
What interventions are being tested in trial NCT07158905?
The interventions under investigation include: Placebo (OTHER), AV-1980R 20 µg (BIOLOGICAL), AV-1980R 60 µg (BIOLOGICAL), AV-1980R 180 µg (BIOLOGICAL).
Who is sponsoring clinical trial NCT07158905?
This trial is sponsored by Institute for Molecular Medicine, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.